盐酸埃克替尼与厄洛替尼治疗化疗失败的晚期肺癌的临床观察

目的观察和比较盐酸埃克替尼与厄洛替尼在化疗失败的晚期非小细胞肺癌患者中的疗效和安全性。方法选择26例晚期化疗失败的非小细胞肺癌患者，随机分人埃克替尼组和厄洛替尼组。其中埃克替尼组13例，厄洛替尼组13例，观察比较两组近期疗效及毒副反应。结果埃克替尼组完全缓解0例，部分缓解3例，稳定5例，有效率为23．1％，疾病控制率61．6％。厄洛替尼组完全缓解0例，部分缓解2例，稳定7例，有效率为15．4％，疾病控制率69．2％。两组有效率及疾病控制率比较差异无统计学意义（P〉0．05）。两组患者毒副反应类似，主要为皮疹，均可耐受。结论埃克替尼在化疗失败的晚期非小细胞肺癌患者中的疗效及不良反应与厄洛替尼相似，是该类患者的新选择。

Clinical Observation of Icotinib Hydrochloride and Erlotinib in the Treatment of Patients with Advanced Lung Cancer Who Failed Previous Chemotherapy

Objective To observe the efficacy and safety of icotinib hydrochloride and erlotinib in the treatment of patients with advanced non-small cell lung cancer who failed previous chemotherapy. Methods 26 patients with advanced non-small cell lung cancer failed previous chemotherapy were selected and randomly divided into icotinib group（13 cases） and erlotinib group （13 cas- es）. The short-term efficacy and side effects of both groups were observed and compared. Results In the icotinib group, there was 0 case of complete remission（CR）, 3 cases of partial remission（PR）, 5 cases of stable disease（SD）, the response rate was 23.1%, and the disease control rate was 61.6%. In the erlotinib group, there was 0 case of CR, 2 cases of PR, 7 cases of SD, the response rate was 15.4% and the disease control rate was 69.2%. There was no statistically significant difference between the groups in response rate and disease control rate （P〉0.05）. The main adverse events occurred in the two groups were similar, mainly were skin rashes, and which could be tolerant. Conclusion The efficacy and safety of icotinib are similar to those of erlotinib in the treatment of pa- tients with advanced non-small cell lung cancer who failed previous chemotherapy, and which is a new choice for these patients.